BROOKS LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.45 INR | -1.04% |
|
-7.89% | -37.01% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,292 | 867.6 | 376.7 | 1,514 | 1,801 | 1,540 |
| Enterprise Value (EV) 1 | 1,566 | 1,154 | 649.1 | 1,919 | 2,027 | 1,605 |
| P/E ratio | -9.36 x | -5.86 x | -1.1 x | -7.82 x | -11.1 x | -7.37 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.32 x | 1.58 x | 0.54 x | 1.95 x | 1.98 x | 2.44 x |
| EV / Revenue | 2.81 x | 2.1 x | 0.93 x | 2.47 x | 2.23 x | 2.54 x |
| EV / EBITDA | -17.6 x | -21 x | -25.2 x | 219 x | -13.9 x | -6 x |
| EV / FCF | -16 x | -54.8 x | -5.48 x | -20.4 x | -4.22 x | 18.2 x |
| FCF Yield | -6.25% | -1.82% | -18.3% | -4.9% | -23.7% | 5.49% |
| Price to Book | 1.13 x | 0.83 x | 0.38 x | 1.91 x | 2.86 x | 2.08 x |
| Nbr of stocks (in thousands) | 16,186 | 16,186 | 24,703 | 24,703 | 24,703 | 24,703 |
| Reference price 2 | 79.85 | 53.60 | 15.25 | 61.30 | 72.90 | 62.35 |
| Announcement Date | 8/11/18 | 8/30/19 | 9/4/20 | 9/7/21 | 9/6/22 | 8/30/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 557.1 | 550.3 | 696.9 | 778.1 | 910.8 | 632 |
| EBITDA 1 | -88.89 | -55.05 | -25.76 | 8.783 | -145.4 | -267.4 |
| EBIT 1 | -153.3 | -119.8 | -89.64 | -60.03 | -216 | -334 |
| Operating Margin | -27.52% | -21.78% | -12.86% | -7.72% | -23.72% | -52.85% |
| Earnings before Tax (EBT) 1 | -175.3 | -149.5 | -135.1 | -89.93 | -239 | -383.8 |
| Net income 1 | -138.1 | -148.1 | -243.8 | -193.8 | -161.9 | -209 |
| Net margin | -24.79% | -26.9% | -34.98% | -24.9% | -17.77% | -33.07% |
| EPS 2 | -8.534 | -9.147 | -13.84 | -7.843 | -6.553 | -8.461 |
| Free Cash Flow 1 | -97.91 | -21.06 | -118.5 | -93.97 | -480.2 | 88.08 |
| FCF margin | -17.57% | -3.83% | -17.01% | -12.08% | -52.73% | 13.94% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/11/18 | 8/30/19 | 9/4/20 | 9/7/21 | 9/6/22 | 8/30/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 273 | 287 | 272 | 405 | 227 | 64.9 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -3.076 x | -5.21 x | -10.58 x | 46.11 x | -1.558 x | -0.2426 x |
| Free Cash Flow 1 | -97.9 | -21.1 | -119 | -94 | -480 | 88.1 |
| ROE (net income / shareholders' equity) | -11.4% | -13.5% | -23.9% | -21.8% | -18.1% | -29.8% |
| ROA (Net income/ Total Assets) | -5.69% | -4.4% | -3.44% | -2.35% | -7.54% | -13.7% |
| Assets 1 | 2,427 | 3,366 | 7,086 | 8,261 | 2,146 | 1,529 |
| Book Value Per Share 2 | 70.70 | 65.00 | 39.80 | 32.00 | 25.50 | 29.90 |
| Cash Flow per Share 2 | 0.4000 | 1.540 | 0.1600 | 0.3600 | 1.050 | 0.0100 |
| Capex 1 | 57.3 | 8.67 | 25.8 | 56.1 | 276 | 4.68 |
| Capex / Sales | 10.29% | 1.58% | 3.71% | 7.21% | 30.32% | 0.74% |
| Announcement Date | 8/11/18 | 8/30/19 | 9/4/20 | 9/7/21 | 9/6/22 | 8/30/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -37.01% | 28.8M | |
| +21.63% | 44.11B | |
| +23.03% | 22.71B | |
| +18.22% | 15.15B | |
| +12.66% | 13.56B | |
| +60.18% | 12.7B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.63B |
- Stock Market
- Equities
- BROOKS Stock
- Financials Brooks Laboratories Limited
